
	Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART&trade; and HSCT/Mucositis&trade;--designed not only to predict a patient&#39;s risk for developing common chemotherapy-related side effects, but also to assess a patient&#39;s willingness to tolerate those side effects. The Company&#39;s novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company&#39;s analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics&#39; goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient&#39;s needs and values.
